|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||
| Subscriptions receivable | ||||||||||||||||||
| Other current assets | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Investments held in Trust Account | ||||||||||||||||||
| Other assets: | ||||||||||||||||||
| Licenses | ||||||||||||||||||
| Patents | ||||||||||||||||||
| Intangibles, net | ||||||||||||||||||
| Investment in equity securities | ||||||||||||||||||
| Deposits for property and equipment | ||||||||||||||||||
| Other non-current assets | ||||||||||||||||||
| Total other assets | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Current liabilities: | ||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Accrued expenses | ||||||||||||||||||
| Total accounts payable and accrued expenses | ||||||||||||||||||
| Notes payable | ||||||||||||||||||
| Assumed Income tax payable from Merger | ||||||||||||||||||
| Other liabilities | ||||||||||||||||||
| Franchise tax payable | ||||||||||||||||||
| Income tax payable | ||||||||||||||||||
| Excise tax liability | ||||||||||||||||||
| Notes payable to related parties | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Warrant liability | ||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||
| Convertible promissory note - related party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Convertible promissory notes | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total convertible promissory notes | ||||||||||||||||||
| Deferred underwriting fee payable | ||||||||||||||||||
| Derivative liability | ||||||||||||||||||
| Deferred income tax payable | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Common stock subject to possible redemption, 1,760,194 shares and 1,760,194 shares at redemption value of $10.69 and $10.55 per share as of March 31, 2024 and December 31, 2023, respectively | ||||||||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||||||
| Preferred stock, par value $0.0001, 100,000,000 shares authorized; 47,940 and 0 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Common stock, par value $0.0001, 1,000,000,000 shares authorized; 158,850,637 and 72,536,722 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Common stock to be issued | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||
Loading...
